Literature DB >> 15984010

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

Niki S Schoonenboom1, Cees Mulder, Gerard J Van Kamp, Sangita P Mehta, Philip Scheltens, Marinus A Blankenstein, Pankaj D Mehta.   

Abstract

Various C-terminally truncated amyloid beta peptides (Abeta) are linked to Alzheimer's disease (AD) pathogenesis. Cerebrospinal fluid (CSF) concentrations of Abeta38, Abeta40, and Abeta42 were measured by enzyme-linked immunosorbent assay in 30 patients with AD and 26 control subjects. CSF Abeta42 levels was decreased in patients with AD, whereas CSF Abeta38 and Abeta40 levels were similar in patients with AD and control subjects. All three Abeta peptides were interrelated, particularly CSF Abeta38 and Abeta40. Diagnostic accuracy of CSF Abeta42 concentrations was not improved by applying the ratios of CSF Abeta42 to Abeta38 or Abeta40.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15984010     DOI: 10.1002/ana.20508

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  37 in total

1.  Novel therapeutic approach for Alzheimer's disease by removing amyloid beta protein from the brain with an extracorporeal removal system.

Authors:  Kazunori Kawaguchi; Nobuya Kitaguchi; Shigeru Nakai; Kazutaka Murakami; Kunihiko Asakura; Tatsuro Mutoh; Yoshiro Fujita; Satoshi Sugiyama
Journal:  J Artif Organs       Date:  2010-02-23       Impact factor: 1.731

2.  Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease.

Authors:  Weiguo Peng; Thiyagarajan M Achariyar; Baoman Li; Yonghong Liao; Humberto Mestre; Emi Hitomi; Sean Regan; Tristan Kasper; Sisi Peng; Fengfei Ding; Helene Benveniste; Maiken Nedergaard; Rashid Deane
Journal:  Neurobiol Dis       Date:  2016-05-24       Impact factor: 5.996

Review 3.  Extracellular Zn2+-Dependent Amyloid-β1-42 Neurotoxicity in Alzheimer's Disease Pathogenesis.

Authors:  Yuichi Sato; Mako Takiguchi; Haruna Tamano; Atsushi Takeda
Journal:  Biol Trace Elem Res       Date:  2020-04-13       Impact factor: 3.738

4.  Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.

Authors:  Magdalena Nutu; Philippe Bourgeois; Henrik Zetterberg; Erik Portelius; Ulf Andreasson; Stéphane Parent; Francesco Lipari; Sara Hall; Radu Constantinescu; Oskar Hansson; Kaj Blennow
Journal:  Neuromolecular Med       Date:  2012-12-07       Impact factor: 3.843

5.  Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

Authors:  Volker Welge; Oliver Fiege; Piotr Lewczuk; Brit Mollenhauer; Hermann Esselmann; Hans-Wolfgang Klafki; Stefanie Wolf; Claudia Trenkwalder; Markus Otto; Johannes Kornhuber; Jens Wiltfang; Mirko Bibl
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

6.  CSF Biomarkers for Alzheimer's Disease Diagnosis.

Authors:  A Anoop; Pradeep K Singh; Reeba S Jacob; Samir K Maji
Journal:  Int J Alzheimers Dis       Date:  2010-06-23

Review 7.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

8.  Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Joel Jakobsson; Henrik Zetterberg; Kaj Blennow; Carl Johan Ekman; Anette G M Johansson; Mikael Landén
Journal:  Neuropsychopharmacology       Date:  2012-11-06       Impact factor: 7.853

9.  A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer's disease.

Authors:  Nobuya Kitaguchi; Midori Hasegawa; Shinji Ito; Kazunori Kawaguchi; Yoshiyuki Hiki; Sigeru Nakai; Nobuo Suzuki; Yasunobu Shimano; Osamu Ishida; Hiroko Kushimoto; Masao Kato; Sigehisa Koide; Kyoko Kanayama; Takashi Kato; Kengo Ito; Hiroshi Takahashi; Tatsuro Mutoh; Satoshi Sugiyama; Yukio Yuzawa
Journal:  J Neural Transm (Vienna)       Date:  2015-07-31       Impact factor: 3.575

10.  Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Authors:  Anne M Fagan; Mark A Mintun; Aarti R Shah; Patricia Aldea; Catherine M Roe; Robert H Mach; Daniel Marcus; John C Morris; David M Holtzman
Journal:  EMBO Mol Med       Date:  2009-11       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.